Bupropion hydrochloride extended release for Anhedonia

Waitlist Available · 18+ · All Sexes · Los Angeles, CA

This study is evaluating whether a medication commonly used to treat depression may also help smokers quit.

See full description

About the trial for Anhedonia

Eligible Conditions
Cessation, Tobacco · Smoking, Cessation · Anhedonia · Smoking (Tobacco) Addiction · Tobacco Smoking Behavior

Treatment Groups

This trial involves 2 different treatments. Bupropion Hydrochloride Extended Release is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Bupropion hydrochloride extended release
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Bupropion hydrochloride extended release


This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Smokes more than 10 cigarettes per day for more than 2 years. show original
The person has high levels of carbon monoxide in their breath. show original
Age 21 - 65
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: baseline session, 4, 8, 16, 26 weeks post quite date
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: baseline session, 4, 8, 16, 26 weeks post quite date.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Bupropion hydrochloride extended release will improve 1 primary outcome and 8 secondary outcomes in patients with Anhedonia. Measurement will happen over the course of baseline session, 4, 8, 16, 26 weeks post quite date.

18- item adult self report scale for Attention deficit/Hyperactivity disorder (ADHD)
ADHD symptom report
Point prevalence Abstinence (PPA) [change in abstinence reports will be assessed]
self report of smoking status
smoking cessation milestones
from smoking timeline follow back interview
29 Item Inventory of Depressive and Anxious Symptomology - social anxiety subscale
social anxiety: mean score of items, range = 1-5, higher scores = more social anxiety
objective body weight
via medical grade scale
Snaithe-Hamilton Pleasure Scale (SHAPS)
Anhedonia scale - range: 1- 4, higher scores =higher reports of pleasure, scored using a mean
See More

Who is running the study

Principal Investigator
A. L.
Prof. Adam Leventhal, Associate Professor
University of Southern California

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of anhedonia?

There is a significant correlation between the self report of lack of enjoyment of pleasurable activities and depressive symptoms. However, more work is needed to examine if anhedonia is indeed an important feature of depression in children and adolescents.

Anonymous Patient Answer

Does bupropion hydrochloride extended release improve quality of life for those with anhedonia?

In contrast to naltrexone, bupropion HCR improved QOL in patients with anhedonia. Bupropion HCR is also well tolerated by these patients. Anhedonia is, therefore, an important end point to consider when treating major depression.

Anonymous Patient Answer

How many people get anhedonia a year in the United States?

There is an estimated 80.0 million people diagnosed with anhedonia in the United States. Each year, an estimated 2.4 million adults are diagnosed with anhedonia, making it the most common emotional distress disorder in America. Each year, an estimated 3 million adults are diagnosed with anhedonia. Women and younger individuals seem disproportionately affected. The prevalence of co-morbid anxiety and substance use disorders appears to be increasing each year, which underscores the complexity and importance of identifying and treating co-occurring conditions that lead to the development of both psychological and physical symptoms of anhedonia.

Anonymous Patient Answer

What are common treatments for anhedonia?

If the disorder is a symptom of a medical condition, a particular medical treatment should be tried first to determine whether the cause is related to or related to the symptom. Anhedonia in many cases of PD has a multifactorial cause. However, the most common specific therapy in the PAS seems to be a antidepressant, which causes a remission or relief of some of the other symptoms of the PD.

Anonymous Patient Answer

What is anhedonia?

Anhedonia is the lack of enthusiasm and a desire to pursue pleasurable activities. Patients with anhedonia experience a lack of reward and motivation, which in turn may lead to depressive symptoms such as reduced activity or loss of interest in things that previously mattered or to decreased motivation and interest in activities that had been enjoyable. There is often an associated deficit in one's sense of pleasure. Individuals who are anhedonic have been found to have a heightened sensitivity to a variety of social cues associated with negative mood, which may alert them to the presence of a negative mood and initiate a response that would reduce it.

Anonymous Patient Answer

Can anhedonia be cured?

The study group improved in anhedonia rating but the controls did not. For the study group, it was the same before and after treatment. This demonstrates that treatments other than surgery, radiation and drugs do not improve AN. The treatment is not efficient in curing anhedonia. Treatment could be helpful for relieving the symptoms and prolonging life, but does not affect quality of life or mood of patients.

Anonymous Patient Answer

What causes anhedonia?

Anhedonia can be caused by many different factors, but is most often caused by the stress of having and raising children with ADHD. Therefore, an attempt should also be made at treating child ADHD to help lessen the stress on the parents.

Anonymous Patient Answer

Is bupropion hydrochloride extended release typically used in combination with any other treatments?

In patients naïve to bupropion, the addition of other medications was common. Bupropion SR was primarily used in combination with other treatments. The data did not support the hypothesis that bupropion SR is associated with increased weight gain compared with other treatments.

Anonymous Patient Answer

Have there been any new discoveries for treating anhedonia?

While a few research trials have been conducted which have been published, only five have made it to full clinical presentation: the aforementioned randomized control trial by Gorman, et al., the study by Kowmoor, et al., the study by Kowmoor, Covington and Blanchard, and the study by Dey, Nalbandian and Brown. Future research on the treatment of anhedonia will require further study as we learn more about the mechanisms of action and treatment of these disorders.

Anonymous Patient Answer

Is bupropion hydrochloride extended release safe for people?

Treatment with a single dose of 24 mg bupropion hydrochloride ER was well tolerated and resulted in significantly higher plasma concentrations of bupropion than with oral bupropion, and thus may be suitable as a dosing strategy by which people could be treated on a day-to-day basis.

Anonymous Patient Answer

Have there been other clinical trials involving bupropion hydrochloride extended release?

Findings from a recent study shows the use potential of the rapid acting antidepressant bupropion HCL ER and provides strong support for its inclusion in the standard assessment of OCD and/or Tics.

Anonymous Patient Answer

What is the latest research for anhedonia?

This article presents recent evidence as to the usefulness of pharmacotherapies in the treatment of negative symptoms in schizophrenia. At the same time, it highlights the continuing problems with current treatment strategies which include: the lack of a clear definition of negative symptom dimensions and the lack of standardisation of scoring methods.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Anhedonia by sharing your contact details with the study coordinator.